Granupas 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended on 
N/0039 
Minor change in labelling or package leaflet not 
18/04/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
23/06/2022 
22/08/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds 
/202110 
aminosalicylic acid (centrally authorised product) 
recommending the variation to terms of the Marketing 
Authorisation(s)’ for PSUSA/10171/202110. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
IA/0037 
A.7 - Administrative change - Deletion of 
10/01/2022 
22/08/2022 
Annex II and PL 
manufacturing sites 
IB/0036 
B.II.d.1.z - Change in the specification parameters 
10/01/2022 
n/a 
and/or limits of the finished product - Other variation 
IA/0035 
A.7 - Administrative change - Deletion of 
12/08/2021 
n/a 
manufacturing sites 
IAIN/0034 
B.II.b.1.a - Replacement or addition of a 
24/06/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
N/0033 
Minor change in labelling or package leaflet not 
28/02/2020 
09/06/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0032/G 
This was an application for a group of variations. 
10/10/2019 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IB/0031 
B.II.b.5.z - Change to in-process tests or limits 
09/10/2019 
n/a 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the finished 
product - Other variation 
IB/0030 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
09/10/2019 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IG/1105/G 
This was an application for a group of variations. 
06/06/2019 
09/06/2020 
Annex II and PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
/201810 
aminosalicylic acid (centrally authorised product) 
R/0026 
Renewal of the marketing authorisation. 
18/10/2018 
18/12/2018 
SmPC, Annex II, 
Based on the review of data on quality, safety and 
Labelling and PL 
efficacy, the CHMP considered that the benefit-risk 
balance of Granupas in the approved indication remains 
favourable and therefore recommended the renewal of 
the marketing authorisation with unlimited validity. 
T/0025 
Transfer of Marketing Authorisation 
21/05/2018 
29/06/2018 
SmPC, Labelling 
and PL 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
17/05/2018 
n/a 
PRAC Recommendation - maintenance 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
/201710 
aminosalicylic acid (centrally authorised product) 
II/0024 
B.II.d.1.e - Change in the specification parameters 
26/04/2018 
n/a 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
26/10/2017 
n/a 
PRAC Recommendation - maintenance 
/201704 
aminosalicylic acid (centrally authorised product) 
IB/0022/G 
This was an application for a group of variations. 
26/07/2017 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
05/05/2017 
n/a 
PRAC Recommendation - maintenance 
/201610 
aminosalicylic acid (centrally authorised product) 
N/0020 
Minor change in labelling or package leaflet not 
18/04/2017 
25/07/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
27/10/2016 
n/a 
PRAC Recommendation - maintenance 
/201604 
aminosalicylic acid (centrally authorised product) 
IB/0018 
B.II.b.5.z - Change to in-process tests or limits 
01/08/2016 
n/a 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the finished 
product - Other variation 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
26/05/2016 
22/07/2016 
SmPC and PL 
Refer to Scientific conclusions and grounds 
/201510 
aminosalicylic acid (centrally authorised product) 
recommending the variation to terms of the Marketing 
Authorisation(s)’ for PSUSA/10171/201510. 
II/0014 
B.II.d.1.e - Change in the specification parameters 
21/07/2016 
25/07/2017 
SmPC, Labelling 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
and PL 
II/0013 
Update of section 5.3 of the SmPC with data from an 
26/05/2016 
22/07/2016 
SmPC 
An in vivo genotoxicity study (micronucleus test) has 
in vivo genotoxicity study (micronucleus test). 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
been conducted with para-aminosalicylic acid. Results 
indicate that para-aminosalicylic acid was considered not 
to have produced any clastogenic effect in mice treated 
at non-toxic dose levels (examined 24 hours after 2 
daily administrations of 312.5 to 1250 mg/kg). 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
06/11/2015 
n/a 
PRAC Recommendation - maintenance 
/201504 
aminosalicylic acid (centrally authorised product) 
IA/0011/G 
This was an application for a group of variations. 
23/06/2015 
n/a 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Member State - Excipient/AS starting material 
IG/0560 
C.I.8.a - Introduction of or changes to a summary of 
20/05/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
PSUSA/10171
Periodic Safety Update EU Single assessment - para-
10/04/2015 
n/a 
PRAC Recommendation - maintenance 
/201410 
aminosalicylic acid (centrally authorised product) 
IG/0509 
C.I.8.a - Introduction of or changes to a summary of 
28/11/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IA/0006 
B.I.b.2.a - Change in test procedure for AS or 
25/06/2014 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
N/0007 
Minor change in labelling or package leaflet not 
18/06/2014 
13/05/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0004 
B.I.a.1.z - Change in the manufacturer of AS or of a 
10/06/2014 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0002 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
10/06/2014 
13/05/2015 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0005 
A.2.a - Administrative change - Change in the 
15/05/2014 
13/05/2015 
SmPC, Annex II, 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(invented) name of the medicinal product for CAPs 
Labelling and PL 
IAIN/0003 
B.II.b.2.c.1 - Change to importer, batch release 
15/05/2014 
13/05/2015 
Annex II and PL 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0001 
B.II.b.1.a - Replacement or addition of a 
15/05/2014 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
